Patient Groups Recommend Overhaul For Failing EU Compassionate Use Programs
Executive Summary
An alliance of patient organizations for rare diseases says most EU member states are not doing enough to help patients with life-threatening diseases get timely access to innovative drugs on compassionate grounds. A time difference of more than three years may exist between patients benefiting from a compassionate use treatment, depending on where they live.
You may also be interested in...
French Introduce Time Limit For Drug Approval Applications After Compassionate-Use Award
Companies wanting to make their unapproved products available to patients under the “temporary use authorization” are facing some changes to the way the rules are implemented.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.